Compare Natera Inc. Common Stock (NTRA) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard High Dividend Yield ETF — how do they compare? Natera Inc. Common Stock trades at $391.06 (market cap $57.03B), while Vanguard High Dividend Yield ETF trades at $160.06 (market cap $100.80B). The key difference: Vanguard High Dividend Yield ETF is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Vanguard High Dividend Yield ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard High Dividend Yield ETF for 140 Days on average.
| NTRA | VYM | |
|---|---|---|
Market Cap | $57.03B | $100.80B |
Volume | 1,131,157 | 1,062,392 |
Sector | Health | — |
52-Week High | $425.64 | $167.03 |
52-Week Low | $179.42 | $138.43 |
Typical Hold Time | 0 Days | 140 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VYM trades at $159.11, down slightly by 0.08% on the day. The ETF shows a bullish technical signal overall, with moving averages supporting an uptrend, though oscillators are neutral. Recent news highlights its consistent dividend yield of 2.42% but questions its performance versus peers like SCHD and IDV. Key support sits at $158, with resistance at $160.
The outlook for VYM hinges on its dividend reliability amid competition from higher-yielding or better-performing ETFs. Risks include exposure to dividend cuts in holdings like Intel and Walgreens. Analyst sentiment is mixed, favoring a hold rating due to moderate returns compared to alternatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard High Dividend Yield ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VYM →
